- Michael Erickson, PhD, promoted to President and CEO effective May 12, 2026.
- Current CEO Jay Mazelsky to become Executive Chair of the Board.
- Erickson currently leads IDEXX’s Global Point of Care Diagnostics and Telemedicine businesses.
- Transition follows a structured succession process overseen by the IDEXX Board.
- Mazelsky to retire following IDEXX’s 2027 annual meeting of shareholders.
Leadership Transition at IDEXX
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, announced that Michael (Mike) Erickson, PhD, has been appointed as the company’s next President and Chief Executive Officer, effective May 12, 2026. Erickson will succeed Jonathan (Jay) Mazelsky, who will assume the role of Executive Chair of the Board of Directors. Mazelsky plans to retire following the company’s 2027 annual meeting of shareholders, ensuring an extended transition period.
Erickson will also join IDEXX’s Board of Directors when he assumes the CEO position.
Experience and Background
Erickson brings nearly 20 years of leadership in healthcare technology and innovation. Since joining IDEXX in 2011, he has held senior roles spanning diagnostics, software, strategy, and corporate accounts, and currently serves as Executive Vice President and General Manager of IDEXX’s Global Point of Care Diagnostics and Telemedicine businesses. Before IDEXX, Erickson was an Associate Principal at McKinsey & Company, advising major pharmaceutical and health service organizations.
Board Endorsement
“Mike’s appointment as the Company’s next President and CEO is the culmination of the IDEXX Board’s thoughtful and robust succession planning process,” said Lawrence D. Kingsley, Independent Non-Executive Chair of the Board. “He has a deep understanding of the business and is uniquely suited to lead IDEXX forward.”
Kingsley also commended Mazelsky’s tenure: “Under Jay’s leadership, IDEXX expanded its innovation-driven growth strategy and global reach. We look forward to his continued contributions as Executive Chair.”
Erickson and Mazelsky on the Transition
“IDEXX is at the center of the veterinary ecosystem and has an immense opportunity to build on our more than 40-year history of innovation,” said Erickson. “I’m honored to lead IDEXX and continue advancing our purpose of enhancing the health and well-being of pets, people, and livestock.”
Mazelsky reflected on his time as CEO: “It has been a privilege to lead IDEXX since 2019. Mike’s deep knowledge of our business makes him the right person to guide IDEXX into the future.”
Information sourced from IDEXX Laboratories’ company press release.
